The investors were not disclosed.
Led by James Breitmeyer, M.D., Ph.D., President and CEO, Oncternal is a clinical-stage oncology company developing novel therapies for both rare and common cancers by focusing on targets that are uniquely expressed within cancer cells. The company is leveraging its scientific and development expertise, as well as academic collaborations, to advance its two pipeline products, cirmtuzumab, an-anti ROR1 monoclonal antibody, and TK216, a small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins.
The company intends to use the proceeds to further clinical development programs for cirmtuzumab and TK216, and to advance preclinical development of a new ROR1-targeted antibody-drug conjugate (ADC) program.
FinSMEs
22/02/2017